Molecular Partners selects MP0730 as CD70-targeting radiotherapy candidate
MOLN•Molecular Partners selected MP0730 as its third targeted alpha radiotherapy program, targeting CD70 in kidney cancer and other cancers. The company expects a first-in-human program to start in the second half of 2027.
1. Candidate selection
Molecular Partners selected MP0730 as its third targeted alpha radiotherapy program. It targets CD70 in kidney cancer and other cancers.
2. Preclinical findings
Preclinical data in tumor-bearing mice showed strong, sustained tumor uptake relative to healthy tissues, including the kidneys, liver and blood. A first-in-human program is expected to start in the second half of 2027.
